Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over Competitors
ALEXANDRIA, Va., Feb. 7, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, announced today new data that showcases the performance of ControlCheck™, the company's next generation of drug diversion monitoring. A new data analysis comparing ControlCheck against other industry solutions from Q1 to Q4 2023 found ControlCheck 6.6 times more likely to detect diversion, setting a new standard for medication safety and security.